Quantcast

Latest Baxter International Stories

2009-04-15 13:46:00

World Hemophilia Day brings together the global bleeding disorders community MONTREAL, April 15 /PRNewswire/ -- Behind every person with hemophilia is a much needed team of support. This April 17 marks the 20th anniversary of World Hemophilia Day where hemophilia organizations around the world increase awareness of hemophilia and other bleeding disorders. This year's World Hemophilia Day campaign, "Together, We Care", focuses on the importance of comprehensive care, which is central to...

2009-04-13 15:00:00

DEERFIELD, Ill., April 13 /PRNewswire-FirstCall/ -- Baxter International (NYSE: BAX), will host a quarterly conference call to discuss its first quarter 2009 financial results on Thursday, April 16, 2009, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please dial 866-238-0637 (domestic) or 703-639-1156 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you. This call is being webcast by...

2009-01-19 15:07:00

DEERFIELD, Ill., Jan. 19 /PRNewswire-FirstCall/ -- Baxter International (NYSE: BAX), will host a quarterly conference call to discuss its fourth quarter 2008 financial results on Thursday, January 22, 2009, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please dial 866- 238-0637 (domestic) or 703-639-1156 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you. This call is being webcast...

2009-01-05 07:00:00

DEERFIELD, Ill. and SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Baxter International Inc. and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the start of a Phase III clinical trial of Baxter's GAMMAGARD LIQUID [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze(TM) Technology) for the treatment of primary immunodeficiency (PID). The purpose of this clinical trial is to...

2008-12-22 11:36:24

The cause of an outbreak of severe adverse reactions that occurred at hemodialysis facilities across the country early this year has been identified. Vials of heparin manufactured by Baxter Healthcare and contaminated with oversulfated chondroitin sulfate (OSCS) have been shown to be responsible for a widespread outbreak of adverse reactions to hemodialysis treatment that affected 152 people and covered 13 states. Reactions to the contaminated heparin included facial edema, or swelling, low...

2008-11-04 18:00:19

Baxter International Inc. (NYSE: BAX) announced today that it will present at the 2008 Annual Credit Suisse Health Care Conference on Wednesday, November 12, 2008 at 8:30 a.m. (MST) or 10:30 a.m. (EST). The live webcast of Baxter's presentation can be accessed from the Baxter corporate website at http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-EventDetails&E ventId=2012057 and will be available for replay through December 11, 2008. Baxter International Inc. develops,...

2008-10-08 09:00:51

While peritoneal dialysis home therapy (PD) was originally introduced 30 years ago to offer patients with kidney failure a better way to filter toxins and fluids from the body overnight or several times a day in the convenience of their home, the economic advantages of PD have taken on increasing importance and visibility due to recent Centers for Medicare and Medicaid Services (CMS) rule changes and legislation affecting reimbursement and patient education. As government officials,...

2008-09-22 09:00:12

DEERFIELD, Ill., Sept. 22 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced initiation of a Phase III clinical trial following U.S. Food and Drug Administration (FDA) review of its investigational new drug application to evaluate GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)], marketed as KIOVIG in European Union, for the treatment of mild-to-moderate Alzheimer's disease. This trial is expected to be the first of two pivotal Phase III trials required to support...

2008-07-30 18:00:54

CHICAGO, July 30 /PRNewswire-USNewswire/ -- Results from clinical trials of three potential Alzheimer's therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008) in Chicago. A related study showed that taking antidementia drugs appears to have a positive impact on extending lifespan in those with Alzheimer's. These reports included: Eighteen-month...

2008-07-30 18:00:22

To: NATIONAL EDITORS Contact: Alzheimers Association media line: +1-312-335-4078, media@alz.org; ICAD 2008 press room, July 27-31: +1-312-949-3253 - Plus, Taking Antidementia Drugs Extends Lifespan Three Years in Alzheimers - CHICAGO, July 30 /PRNewswire-USNewswire/ -- Results from clinical trials of three potential Alzheimers therapies raise hope for new and better treatments of the disease, according to data reported today at the 2008 Alzheimers Association International Conference...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related